BioSpace News Archive

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and nine months ended September 30, 2019.

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the third quarter ended September 30, 2019.

ViewRay, Inc. announced that the Company will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference in New York, New York. Scott Drake, President and CEO, will give a presentation at 1:30p.m. Eastern Time on Wednesday, December 4, 2019.

CNS Pharmaceuticals, Inc. announced Chief Executive Officer of CNS Pharmaceuticals, John M. Climaco, along with founder, Waldemar Priebe, PhD, and members of management, including, Chief Medical Officer, Sandra Silberman, MD, PhD, Chief Scientific Officer, Donald Picker, PhD, and scientific advisory board member, Sigmund Hsu, MD, PhD, will be attending the 24th Annual Meeting of the Society of Neuro-Oncology.

Harmony Biosciences, LLC (Harmony) announced today that data from two clinical studies evaluating the long-term safety and efficacy, as well as the human abuse potential of WAKIX® (pitolisant), have been published in SLEEP

Athira Pharma, Inc. announced that data from the completed Phase 1 clinical trial of its lead development candidate, NDX-1017, a novel small molecule therapeutic for cognitive enhancement in Alzheimer’s disease, will be presented at the upcoming 12th Annual Clinical Trials on Alzheimer’s Disease Conference taking place December 4-7, 2019 in San Diego, CA.

Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, announced today that it has dosed the first patient in its Phase 1/1b study of PMD-026, the company’s lead product candidate.

DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today a $492,000 award in support of the project entitled “Circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration.”

Forensic scientists now have access to the Applied Biosystems SeqStudio Genetic Analyzer for Human Identification, an affordable and easy-to-use capillary electrophoresis (CE) platform that is able obtain gold-standard quality STR-based DNA profiles without compromising performance.